The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

PSI is recognized as a remarkably stable CRO in an industry known for its unpredictability. Since the company’s establishment ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Robert F. Kennedy Jr., nominated to be health secretary, seemed unfamiliar with the particulars of the massive insurance ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

Pharmaceutical executives are near unanimous (with 68% strongly agreeing and 31% somewhat agreeing) in their concern about a marked increase in theft, fraud, and/or attacks in the pharmaceutical ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.